Meiji Yasuda Asset Management Reduces Incyte Corporation Stake

Institutional investor trims position in biopharmaceutical company

Published on Mar. 9, 2026

Got story updates? Submit your updates here. ›

Meiji Yasuda Asset Management Co Ltd. has reduced its stake in Incyte Corporation (NASDAQ:INCY) by 29.2% in the third quarter, according to a disclosure with the Securities & Exchange Commission. The firm now owns 27,630 shares of the biopharmaceutical company's stock, valued at $2.34 million.

Why it matters

This filing provides insight into the investment activity of Meiji Yasuda Asset Management, a major institutional investor. Changes in large investor positions can signal shifts in market sentiment around a company's stock.

The details

Meiji Yasuda Asset Management sold 11,408 shares of Incyte during the third quarter, reducing its total position to 27,630 shares. The firm cited unspecified reasons for the reduction in its Incyte holdings.

  • Meiji Yasuda Asset Management filed the 13F disclosure for the third quarter of 2026.

The players

Meiji Yasuda Asset Management Co Ltd.

A Japanese asset management firm that invests in various sectors, including the biopharmaceutical industry.

Incyte Corporation

A Wilmington, Delaware-based biopharmaceutical company focused on developing novel therapies in oncology and inflammation.

Got photos? Submit your photos here. ›

The takeaway

This filing indicates that Meiji Yasuda Asset Management has reduced its exposure to Incyte Corporation, potentially signaling a shift in the firm's outlook on the biopharmaceutical company's prospects. Investors will likely monitor any further changes in large institutional positions as a gauge of market sentiment around Incyte.